| dc.contributor.author | Newton, G | |
| dc.contributor.author | Schneider, M | |
| dc.contributor.other | Chapman, K | |
| dc.contributor.other | Perrior, T | |
| dc.contributor.other | Aqil, R | |
| dc.contributor.other | Jarvis, A | |
| dc.coverage.spatial | International | |
| dc.date.accessioned | 2020-08-19T09:50:48Z | |
| dc.date.issued | 2019-04-18 | |
| dc.identifier | GB2018052936W | |
| dc.identifier | WO2019073253 | |
| dc.identifier.citation | 2019 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3984 | |
| dc.description.abstract | This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, for example in a method of treatment. There are also provided processes for producing compounds of the present invention and method of their use. In particular, the present invention relates to compounds of formula (I). | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.subject | Kinase | |
| dc.subject | Cardiovascular | |
| dc.title | MAP4K4 Inhibitors | |
| dc.type | Patent | |
| rioxxterms.licenseref.startdate | 2019-04-18 | |
| rioxxterms.type | Other | |
| pubs.filed-date | 2017-10-13 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
| pubs.patent-status | PCT | |
| pubs.publication-status | Published | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Medicinal Chemistry 3 | en_US |
| dc.contributor.icrauthor | Newton, Gary | |
